1 Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119-1132.
2 Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85-90.
3 Gallou C, Joly D, Mejean A, Staroz F, Martin N, Tarlet G et al. Mutations of the VHL gene in sporadic renal cell carcinoma: Definition of a risk factor for VHL patients to develop an RCC. Human Mutation. 1999;13:464-475.
4 Schraml P, Struckmann K, Hatz F, Sonnet S, Kully C, Gasser T et al. VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. Journal of Pathology. 2002;196:186-193.
5 Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994;91:9700-9704.
6 Kaelin WG. Von Hippel-Lindau disease. Annu Rev Pathol. 2007;2:145-173.
7 Brugarolas J. Renal-cell carcinoma - Molecular pathways and therapies. N Engl J Med. 2007;356:185-187.
8 Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med. 2017;376:354-366.
9 Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-124.
10 Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-2281.
11 Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
12 Dizman N, Philip EJ, Pal SK. Genomic profiling in renal cell carcinoma. Nat Rev Nephrol. 2020;16:435-451.
13 Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22:4991-5004.
14 Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E et al. The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23:313-326.e315.
15 de Cubas AA, Rathmell WK. Epigenetic modifiers: activities in renal cell carcinoma. Nat Rev Urol. 2018;15:599-614.
16 Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43-49.
17 Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010;463:360-363.
18 Guo G, Gui Y, Gao S, Tang A, Hu X, Huang Y et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet. 2011;44:17-19.
19 Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469:539-542.
20 Kanu N, Grönroos E, Martinez P, Burrell RA, Yi Goh X, Bartkova J et al. SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair. Oncogene. 2015;34:5699-5708.
21 Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-892.
22 Nishida J, Momoi Y, Miyakuni K, Tamura Y, Takahashi K, Koinuma D et al. Epigenetic remodelling shapes inflammatory renal cancer and neutrophil-dependent metastasis. Nat Cell Biol. 2020;22:465-475.
23 Joosten SC, Smits KM, Aarts MJ, Melotte V, Koch A, Tjan-Heijnen VC et al. Epigenetics in renal cell cancer: mechanisms and clinical applications. Nat Rev Urol. 2018;15:430-451.
24 Gao L, Emperle M, Guo Y, Grimm SA, Ren W, Adam S et al. Comprehensive structure-function characterization of DNMT3B and DNMT3A reveals distinctive de novo DNA methylation mechanisms. Nat Commun. 2020;11:3355.
25 Pfeifer GP. Defining Driver DNA Methylation Changes in Human Cancer. Int J Mol Sci. 2018;19.
26 Baubec T, Colombo DF, Wirbelauer C, Schmidt J, Burger L, Krebs AR et al. Genomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation. Nature. 2015;520:243-247.
27 Gagliardi M, Strazzullo M, Matarazzo MR. DNMT3B Functions: Novel Insights From Human Disease. Front Cell Dev Biol. 2018;6:140.
28 Zhang Y, Charlton J, Karnik R, Beerman I, Smith ZD, Gu H et al. Targets and genomic constraints of ectopic Dnmt3b expression. Elife. 2018;7.
29 Taguchi L, Miyakuni K, Morishita Y, Morikawa T, Fukayama M, Miyazono K et al. c-Ski accelerates renal cancer progression by attenuating transforming growth factor β signaling. Cancer Sci. 2019;110:2063-2074.
30 Nishida J, Miyazono K, Ehata S. Decreased TGFBR3/betaglycan expression enhances the metastatic abilities of renal cell carcinoma cells through TGF-β-dependent and -independent mechanisms. Oncogene. 2018;37:2197-2212.
31 Murai F, Koinuma D, Shinozaki-Ushiku A, Fukayama M, Miyaozono K, Ehata S. EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway. Cell Discov. 2015;1:15026.
32 Yokoyama Y, Watanabe T, Tamura Y, Hashizume Y, Miyazono K, Ehata S. Autocrine BMP-4 Signaling Is a Therapeutic Target in Colorectal Cancer. Cancer Res. 2017;77:4026-4038.
33 Takahashi K, Ehata S, Koinuma D, Morishita Y, Soda M, Mano H et al. Pancreatic tumor microenvironment confers highly malignant properties on pancreatic cancer cells. Oncogene. 2018;37:2757-2772.
34 Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov. 2017;16:241-263.
35 Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet. 1999;21:163-167.
36 Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 2000;16:168-174.
37 Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP. Hypomethylation of DNA from benign and malignant human colon neoplasms. Science. 1985;228:187-190.
38 Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005;2 Suppl 1:S4-11.
39 Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002;416:552-556.
40 Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360:2289-2301.
41 Mizuno S, Chijiwa T, Okamura T, Akashi K, Fukumaki Y, Niho Y et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood. 2001;97:1172-1179.
42 Takahashi K, Ehata S, Miyauchi K, Morishita Y, Miyazawa K, Miyazono K. Neurotensin receptor 1 signaling promotes pancreatic cancer progression. Mol Oncol. 2021;15:151-166.
43 Chen WC, Chen MF, Lin PY. Significance of DNMT3b in oral cancer. PLoS One. 2014;9:e89956.
44 Quan Z, He Y, Luo C, Xia Y, Zhao Y, Liu N et al. Interleukin 6 induces cell proliferation of clear cell renal cell carcinoma by suppressing hepaCAM via the STAT3-dependent up-regulation of DNMT1 or DNMT3b. Cell Signal. 2017;32:48-58.
45 Karimzadeh MR, Pourdavoud P, Ehtesham N, Qadbeigi M, Asl MM, Alani B et al. Regulation of DNA methylation machinery by epi-miRNAs in human cancer: emerging new targets in cancer therapy. Cancer Gene Ther. 2020.
46 Roquid KAR, Alcantara KMM, Garcia RL. Identification and validation of mRNA 3'untranslated regions of DNMT3B and TET3 as novel competing endogenous RNAs of the tumor suppressor PTEN. Int J Oncol. 2020;56:544-558.
47 Wu H, Zhang W, Wu Z, Liu Y, Shi Y, Gong J et al. miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma. Cell Death Dis. 2019;10:48.
48 Baylin SB, Jones PA. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol. 2016;8.
49 Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res. 2005;11:1203-1209.
50 Nosho K, Shima K, Irahara N, Kure S, Baba Y, Kirkner GJ et al. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res. 2009;15:3663-3671.
51 Llorca-Cardeñosa MJ, Fleitas T, Ibarrola-Villava M, Peña-Chilet M, Mongort C, Martinez-Ciarpaglini C et al. Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. Oncotarget. 2016;7:63424-63436.
52 Krassenstein R, Sauter E, Dulaimi E, Battagli C, Ehya H, Klein-Szanto A et al. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res. 2004;10:28-32.
53 Modena P, Testi MA, Facchinetti F, Mezzanzanica D, Radice MT, Pilotti S et al. UQCRH gene encoding mitochondrial Hinge protein is interrupted by a translocation in a soft-tissue sarcoma and epigenetically inactivated in some cancer cell lines. Oncogene. 2003;22:4586-4593.
54 Smith PM, Fox JL, Winge DR. Reprint of: Biogenesis of the cytochrome bc1 complex and role of assembly factors. Biochim Biophys Acta. 2012;1817:872-882.
55 Ndi M, Marin-Buera L, Salvatori R, Singh AP, Ott M. Biogenesis of the bc1 complex of the mitochondrial respiratory chain. J Mol Biol. 2018;430:3892-3905.
56 Kim CH, King TE. A mitochondrial protein essential for the formation of the cytochrome c1-c complex. Isolation, purification, and properties. J Biol Chem. 1983;258:13543-13551.
57 Nakai M, Endo T, Hase T, Tanaka Y, Trumpower BL, Ishiwatari H et al. Acidic regions of cytochrome c1 are essential for ubiquinol-cytochrome c reductase activity in yeast cells lacking the acidic QCR6 protein. J Biochem. 1993;114:919-925.
58 Gao F, Liu Q, Li G, Dong F, Qiu M, Lv X et al. Identification of ubiquinol cytochrome c reductase hinge (UQCRH) as a potential diagnostic biomarker for lung adenocarcinoma. Open Biol. 2016;6.
59 Yang M, Trumpower BL. Deletion of QCR6, the gene encoding subunit six of the mitochondrial cytochrome bc1 complex, blocks maturation of cytochrome c1, and causes temperature-sensitive petite growth in Saccharomyces cerevisiae. J Biol Chem. 1994;269:1270-1275.
60 Okazaki M, Ishibashi Y, Asoh S, Ohta S. Overexpressed mitochondrial hinge protein, a cytochrome c-binding protein, accelerates apoptosis by enhancing the release of cytochrome c from mitochondria. Biochem Biophys Res Commun. 1998;243:131-136.
61 Luo Y, Medina Bengtsson L, Wang X, Huang T, Liu G, Murphy S et al. UQCRH downregulation promotes Warburg effect in renal cell carcinoma cells. Sci Rep. 2020;10:15021.
62 Dudek J. Role of cardiolipin in mitochondrial signaling pathways. Front Cell Dev Biol. 2017;5:90.
63 Briehl MM. Oxygen in human health from life to death--An approach to teaching redox biology and signaling to graduate and medical students. Redox Biol. 2015;5:124-139.
64 Perier C, Tieu K, Guegan C, Caspersen C, Jackson-Lewis V, Carelli V et al. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A. 2005;102:19126-19131.